U.S. Markets closed

Sonnet BioTherapeutics Holdings, Inc. (SONN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0000-0.0700 (-3.38%)
At close: 4:00PM EDT

2.0700 +0.06 (2.99%)
After hours: 7:59PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.0700
Open2.0400
Bid2.0000 x 2200
Ask2.0300 x 800
Day's Range1.9200 - 2.0600
52 Week Range1.8100 - 16.2000
Volume486,063
Avg. Volume1,158,638
Market Cap35.112M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 17, 2021 - May 21, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Sonnet BioTherapeutics Provides 2021 Business Update

    PRINCETON, NJ / ACCESSWIRE / March 29, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today a business update on its ongoing programs.

  • ACCESSWIRE

    Sonnet BioTherapeutics Appoints Richard Kenney as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations

    PRINCETON, NJ / ACCESSWIRE / March 22, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today the appointment of Richard Kenney, M.

  • ACCESSWIRE

    Sonnet BioTherapeutics Provides Fiscal Year 2021 First Quarter Business and Earnings Update

    SONN-1010, fully human IL-12 configured using FHAB platform, Non-Human Primate study informs pharmacokinetic profileLaunch of At-The-Market Offering Program for up to $15,875,000 of common stockPRINCETON, NJ / ACCESSWIRE / February 16, 2021 / . * SONN-1010, fully human IL-12 configured using FHAB platform, Non-Human Primate study informs pharmacokinetic profile * Launch of At-The-Market Offering Program for up to $15,875,000 of common stockPRINCETON, NJ / ACCESSWIRE / February 16, 2021 / Sonnet BioTherapeutics Holdings, Inc.